Clomacran

Summary

Clomacran (CHEMBL1615350) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 300.8 Da · C18H21ClN2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1615350
Name	Clomacran
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	21382
Molecular formula	C18H21ClN2
Molecular weight	300.8
InChIKey	JFRLWWDJCFYFSU-UHFFFAOYSA-N

SMILES: CN(C)CCCC1C2=CC=CC=C2NC3=C1C=C(C=C3)Cl

IUPAC name: 3-(2-chloro-9,10-dihydroacridin-9-yl)-N,N-dimethylpropan-1-amine

Also known as: Clomacran, Clomacrane, clomacran, CLOMACRAN

Parent form; salt/anhydrous children: CHEMBL2104136

Patent coverage: 127 distinct patent families (520 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 517 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).